ArticleVaccine2008
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Rhabdoviruses as vectors for vaccines and therapeutics.Current opinion in virology · 2020Review
- Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.Journal of virology · 2017Article
- Plague Vaccine Development: Current Research and Future Trends.Frontiers in immunology · 2016Review
- Plague Vaccines: Status and Future.Advances in experimental medicine and biology · 2016Review
- A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Journal of virology · 2015Article
- Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.Infection and immunity · 2013Article
- A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.Journal of virology · 2013Article
- Plague vaccines: current developments and future perspectives.Emerging microbes & infections · 2012Review
- The synthetic futures of vesicular stomatitis virus.Trends in biotechnology · 2012Article
- Article
- The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Journal of virology · 2012Article
- An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.PLoS neglected tropical diseases · 2012Article
- Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.Clinical and vaccine immunology : CVI · 2011Article
- Developing live vaccines against plague.Journal of infection in developing countries · 2011Review
- Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.Journal of virology · 2011Article
- Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria.Frontiers in microbiology · 2011Article
- TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.Vaccine · 2010Article
- Protection against pneumonic plague following oral immunization with a non-replicating vaccine.Vaccine · 2010Article
- Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.Vaccine · 2010Article
- D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.Infection and immunity · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We have developed an experimental recombinant vesicular stomatitis virus (VSV) vectored plague vaccine expressing a secreted form of Yersinia pestis low calcium response protein V (LcrV) from the first position of the VSV genome. This vector, given intramuscularly in a single dose, induced high-level antibody titers to LcrV and gave 90-100% protection against pneumonic plague challenge in mice. This single-dose protection was significantly better than that generated by VSV expressing the non-secreted LcrV protein. Increased protection correlated with increased anti-LcrV antibody and a bias toward IgG2a and away from IgG1 isotypes. We also found that the depletion of CD4+ cells, but not CD8+ cells, at the time of challenge resulted in reduced vaccine protection, indicating a role for cellular immunity in protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.